La Jolla Pharmaceutical Company (LJPC)
(Delayed Data from NSDQ)
$8.26 USD
+0.22 (2.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[LJPC]
Reports for Purchase
Showing records 1 - 20 ( 72 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Mixed Results for LJPC-401; CEO Dr. Tidmarsh Departs; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
3Q19 Results; LJPC-401 Topline Phase 2 Data Projected for This Quarter: Lowering PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Giapreza Receives European Commission''s Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
2Q19 Results; MAA Decision Expected for Giapreza This Quarter Could Be a Stock Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
FDA Grants Orphan Drug Designation for LJPC-0118 to Treat Malaria
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Win for La Jolla Interim Phase 2 Data in Hereditary Hemochromatosis Looks Good
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
1Q19 Results; Giapreza Sales Slightly Lower Than Expected, Operating Expense Cuts Lead to EPS Beat; Adj PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
La Jolla Announces FDA Breakthrough Therapy Designation for LJPC-0118 in Severe Malaria
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
La Jolla Reports 4Q18 Results; Giapreza and Platform Updates; PT to $26 from $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
La Jolla Pharmaceutical Announces Key Objectives for 2019; Revenue Guidance Well Below Our Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Giapreza U.S. Launch Progressing; Europe Launch Expected 2H19; Revising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Global Investment Conference: La Jolla Takeaways; Giapreza, Pipeline Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
La Jolla Pharma 2Q18 Results; Giapreza on Formularies of Over 200 Hospitals
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
1Q18 Results: $125M Royalty Financing Agreement Announced; Price Target Lowered to $72 From $83
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E